Propofol is a unique highly lipid-soluble anesthetic that is formulate
d in a fat emulsion (Diprivan) for intravenous (iv) use. It has the de
sirable properties of rapid onset and offset of effect following rapid
iv administration and minimal accumulation on long-term administratio
n. Based on physicochemical properties and preliminary brain solubilit
y data, propofol should have an extended effect-site turnover and a re
sulting prolonged effect. However, a preliminary study in humans has r
eported a rapid blood-brain equilibration half-time (T-1/2 k(E0)) Of o
nly 2.9 min. We used a chronically instrumented rat model to examine t
he unique disposition and electroencephalographic (EEG) pharmacodynami
cs of propofol. Although the pharmacokinetics were variable, there was
low interindividual variability in the concentration-EEG effect relat
ionship. The duration of EEG sleep was 26 (+/-44% CV) min following 11
-15 mg/kg doses of propofol. The T-1/2 k(E0) was 1.7 (+/-32%) min. App
arent effect-site concentrations of 0.5-1 mu g/mL were required to mai
ntain sleep in rats. Like other general anesthetics, the concentration
-EEG effect relationship of propofol is biphasic. At a propofol concen
tration of 0.6 (+/-35%) mu g/mL, the number of EEG waves/s was maximal
at 175% of baseline awake state. Further increases in the concentrati
on of propofol depressed EEG activity until complete suppression occur
red at 7 (+/-22%) mu g/mL.